Skip to content
Clinical Trials – home

Hospital Universitario Basurto

Research site

Spain Montevideo Etorbidea 16-18, 48013 Bilbao, Spain

  • 51 trials recruiting
  • Hormone receptor positive HER2 negative breast cancer · Breast cancer · HER2 positive breast cancer
  • Adults and children

About Specializations

Hospital Universitario Basurto in Bilbao, Spain specialises in clinical trials of conditions such as Hormone receptor positive HER2 negative breast cancer, Breast cancer, HER2 positive breast cancer, Non-small cell lung cancer, and other specialisations. This site conducts important research.

Main research areas of the site

Hematology and Blood Disorders

The Hematología department at Hospital Universitario Basurto is active in studies of hematic and lymphatic diseases, with a strong focus on cancers and immune-related blood conditions. Research here includes acute myeloid leukemia, chronic myeloid leukemia, paroxysmal nocturnal hemoglobinuria, and peripheral T-cell lymphoma, reflecting an effort to improve treatment options and long-term disease control.

  • Testing new therapies for blood cancers and rare hematologic disorders
  • Evaluating treatment effectiveness in leukemia and lymphoma
  • Studying immune-based approaches for blood-related diseases

These trials aim to expand options for patients with complex blood diseases while supporting safer and more effective care.

Breast and Gynecologic Oncology

One of the most prominent research areas at this site is neoplasms, especially breast cancer. Trials cover early and advanced disease, including HER2-positive, HER2-negative, and triple-negative breast cancer, as well as locoregional recurrence and metastatic disease. The research is centered on improving outcomes with newer cancer therapies and refining treatment strategies for different tumor subtypes.

  • Testing targeted and antibody-based treatments for breast cancer
  • Evaluating therapies for high-risk, recurrent, and metastatic disease
  • Studying ways to improve survival and reduce relapse

At Hospital Universitario Basurto, this oncology portfolio shows a strong commitment to personalized cancer care.

Lung Cancer and Thoracic Oncology

Clinical research in respiratory tract diseases includes a substantial number of studies in non-small cell lung cancer and small cell lung cancer. The trials address newly diagnosed, locally advanced, and metastatic disease, with attention to biomarker-driven subgroups such as KRASG12C and HER2 alterations. The overall goal is to improve response rates, disease control, and long-term outcomes in lung cancer.

  • Testing new immunotherapy and targeted treatment options
  • Improving care for advanced and resectable lung cancer
  • Exploring biomarker-guided approaches to treatment selection

This area also includes studies designed to strengthen treatment effectiveness after surgery or chemoradiotherapy.

Autoimmune and Inflammatory Diseases

The site is also highly active in immune system diseases and phenomena and processes related to inflammation. Research includes rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus, Sjögren’s syndrome, and giant cell arteritis. These studies are focused on reducing disease activity, easing symptoms, and improving daily functioning for people with chronic autoimmune conditions.

  • Evaluating new immune-modulating therapies
  • Measuring symptom relief and disease control
  • Studying treatment options for difficult-to-manage inflammatory disorders

The research portfolio also includes related conditions affecting nerves and connective tissue, showing broad expertise in inflammatory disease care.

Dermatology and Allergic Conditions

Research in skin and connective tissue diseases includes studies of atopic dermatitis, chronic inducible urticaria, nummular dermatitis, and allergic rhinoconjunctivitis. These trials are designed to test new treatment approaches, improve long-term symptom control, and support better quality of life for patients with persistent allergic and inflammatory skin conditions.

  • Testing therapies for moderate-to-severe eczema and related skin diseases
  • Evaluating options for chronic itching and urticaria
  • Improving control of allergy-driven symptoms

The dermatology program adds important breadth to the clinical research profile of Hospital Universitario Basurto.

Neurology and Neuromuscular Disorders

Studies in nervous system diseases and related immune processes include multiple sclerosis, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and multifocal motor neuropathy. The main purpose of these trials is to assess new treatments that may help control symptoms, prevent relapses, and preserve neurological function over time.

  • Evaluating therapies for autoimmune nerve and muscle disorders
  • Assessing long-term disease control in chronic neurological illness
  • Supporting research into improved functional outcomes

These investigations reflect a strong interest in immune-mediated neurological disease at the site.

Cardiovascular, Metabolic, and Renal Research

The trial portfolio also spans cardiovascular diseases, nutritional and metabolic diseases, and kidney-related care. Research includes atherosclerotic cardiovascular disease, spontaneous coronary artery dissection, heart failure, type 2 diabetes, and end-stage kidney disease. These studies seek better ways to prevent complications, improve disease management, and evaluate the effectiveness of newer treatments.

  • Testing therapies to reduce cardiovascular events and improve heart health
  • Studying glucose control in diabetes
  • Evaluating care approaches for kidney disease and dialysis-related needs

This area shows a broad interest in chronic disease management and prevention.

Urologic and Genitourinary Oncology

Another important field is male urogenital diseases and female urogenital diseases, especially bladder cancer, upper tract urothelial carcinoma, and prostate cancer. The studies are aimed at improving treatment effectiveness, supporting surgery-related decision-making, and exploring better options for patients with recurrent, high-risk, or advanced disease.

  • Evaluating new treatments for bladder and urinary tract cancers
  • Studying approaches for high-risk non-muscle invasive disease
  • Assessing treatment strategies in advanced prostate cancer

The research activity here highlights a strong oncology focus beyond breast and lung cancer.

Other Specialized Research Areas

The site also conducts studies in several additional therapeutic areas, including digestive system diseases, eye diseases, musculoskeletal diseases, hormonal diseases, and virus diseases. Examples include idiopathic pulmonary fibrosis, progressive fibrosing interstitial lung disease, transthyretin amyloidosis, and HIV infections, showing a wide-ranging clinical research program that extends beyond its core hematology expertise.

  • Testing treatments for rare and chronic multisystem diseases
  • Improving long-term safety and symptom control
  • Exploring new options across diverse medical specialties

Across these areas, Hospital Universitario Basurto supports research aimed at practical improvements in patient care.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Montevideo Etorbidea 16-1848013 BilbaoSpain
Recruiting now
51 trials
Conditions studied
95

More sites in BilbaoSpain

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

171 clinical trials

Phase 2 Study of Nemolizumab for Skin Thickening in Adults with Systemic Sclerosis

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Nemolizumab
  • Sponsor:Galderma S.A.

Eczema nummular

Recruiting

A study to evaluate the effectiveness and safety of lebrikizumab in adults with nummular eczema who do not respond well to topical corticosteroids.

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Lebrikizumab
  • Sponsor:Almirall S.A.

Study of nadofaragene firadenovec alone or with gemcitabine, docetaxel or pembrolizumab in adults with non-muscle invasive bladder cancer who did not respond to BCG therapy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Ferring Pharmaceuticals A/S

Breast cancer

Recruiting

Study on the Safety and Effectiveness of Trastuzumab Deruxtecan vs. Palbociclib-Based Drug Combination for Advanced HR-Positive, HER2-Low Breast Cancer Patients

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Medica Scientia Innovation Research S.L.

Study of Nadofaragene Firadenovec for Adults with Intermediate Risk Non-Muscle Invasive Bladder Cancer

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Nadofaragene firadenovec
  • Sponsor:Ferring Pharmaceuticals A/S

Study on Seltorexant for Adults and Elderly with Major Depressive Disorder and Insomnia Symptoms

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Seltorexant
  • Sponsor:Janssen Cilag International

Adjuvant Therapy with RO7435846 (divarasib) versus Pembrolizumab or Nivolumab or Observation in Patients After Surgery for Stage II‑III KRAS G12C NSCLC

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Divarasib
  • Sponsor:F. Hoffmann-La Roche AG

Breast cancer+1

Recruiting

Evaluation of zongertinib, fulvestrant and goserelin acetate in patients with HR‑positive HER2‑negative advanced breast cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Fulvestrant
  • Sponsor:Medica Scientia Innovation Research S.L.

Safety and effectiveness of ponatinib and asciminib in chronic myeloid leukemia patients resistant to these drugs

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Ponatinib
  • Sponsor:Grupo Espanol De Leucemia Mieloide Cronica (GELMC)

Long-Term Safety Study of Asciminib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Bosutinib
  • Sponsor:Novartis Pharma AG

Cardiac failure+1

Recruiting

Study of Zenagamtide (NNC0487-0111) versus placebo in patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:POLYPEPTIDE CONSISTING OF A GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST AND AN AMYLIN RECEPTOR AGONIST, CONNECTED BY A LINKER WITH 4 GLYCINE RESIDUES, AND CONNECTED TO A C18 FATTY ACID SIDE CHAIN
  • Sponsor:Novo Nordisk A/S

Hidradenitis

Recruiting

A safety and efficacy study of SAR445399 in adults with moderate to severe hidradenitis suppurativa

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:SAR445399
  • Sponsor:Sanofi-Aventis Recherche & Developpement
Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.